Literature DB >> 1816153

Reconstruction of the chronically lax anterior cruciate ligament using the middle third of the patellar tendon. A 3-9 year follow-up.

P Aglietti1, R Buzzi, S D'Andria, A Pisaneschi, G Zaccherotti.   

Abstract

After an average of 5 years, the authors reviewed 76 cases of anterior cruciate ligament reconstruction in which the middle third of the patellar tendon had been used as a free autogenous graft. A lateral Lemaire operation had been used in 85% of the cases and postoperative cast immobilization in 72%. Functional knee instability was eliminated in 96% of the patients. Pain was present at the follow-up in 14.5% of the patients and correlated with both meniscectomy (p = 0.03) and the presence of degenerative changes on the radiographs (p = 0.002). The pivot-shift was eliminated in 93% of the cases and the maximum manual test performed with the KT-1000 arthrometer was less than or equal to 5 mm in 83%. Lateral compartment laxity which was not corrected at operation was frequently associated with graft failure (p = 0.01). Seven patients had difficulty in rehabilitation, and in 6 of these the final result was unsatisfactory. Pain and swelling in the femoropatellar joint were present in 8% of the cases. Slight and moderate degenerative changes were shown on the radiographs in 48% and 10% of the patients, respectively, at follow-up; these findings correlated with meniscectomy (p less than 0.001) and rehabilitation problems (p = 0.03). This procedure achieved lasting, satisfactory results in 70% of the cases. Additional advances include greater care in positioning the graft, use of arthroscopy, and early mobilization. Further studies are needed to verify the advantages of these new techniques.

Entities:  

Mesh:

Year:  1991        PMID: 1816153

Source DB:  PubMed          Journal:  Ital J Orthop Traumatol        ISSN: 0390-5489


  1 in total

1.  Anterior cruciate reconstruction with the ABC carbon and polyester prosthetic ligament.

Authors:  A C Campbell; P S Rae
Journal:  Ann R Coll Surg Engl       Date:  1995-09       Impact factor: 1.891

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.